Top Markets
#1 MowCat MowCat +48.69%
#2 Bitway Bitway +30.40%
#3 Velvet Velvet +25.26%
#4 Fake World Assets Fake World Assets +24.64%
#5 aPriori aPriori +22.24%
#6 OVERTAKE OVERTAKE +17.93%
#7 Zerebro Zerebro +14.80%
#8 Biconomy Biconomy +13.31%
#9 Palladium Network Palladium Network +12.49%
#10 Derive Derive +12.34%
Coin of the day
MowCat MowCat
설정
언어
한국어
통화
USD
테마
Nicox S.A. Nicox S.A.

Nicox S.A.

COX
주식 순위 #34243
Nicox S.A. is an ophthalmology enterprise operating both within France and... Nicox S.A. is an ophthalmology enterprise operating both within France and globally, focused on developing therapies to safeguard vision and enhance overall eye health. Its leading investigational drug, NCX 470, an innovative nitric oxide-donating prostaglandin analog designed to decrease intraocular pressure in individuals with open-angle glaucoma or ocular hypertension, is currently undergoing Phase 3 clinical trials. Furthermore, the company is progressing NCX 4251, a specialized fluticasone formulation, through a Phase 2b clinical trial for the management of acute exacerbations of blepharitis, as well as NCX 1728. Nicox also provides VYZULTA, a latanoprostene bunod ophthalmic solution for treating open-angle glaucoma or ocular hypertension, and ZERVIATE, a cetirizine ophthalmic solution to relieve ocular itching related to allergic conjunctivitis. The company, established in 1996, has its main office situated in Valbonne, France.
주가
$0.6379482
마지막 동기화: 2023-05-22
시가총액
$5.98M
변동 (1일)
-0.44%
변동 (1년)
0.00%
국가
FR
거래 Nicox S.A. (COX)

카테고리

Healthcare
Nicox S.A. (COX)의 주식 분할 이력
Nicox S.A. 주식 (심볼: COX)은 총 0회의 주식 분할을 거쳤습니다.
가장 최근의 분할은 Aug 16, 2026에 발생했습니다.
Aug 16, 2026 이전에 매수한 COX 주식 1주는 현재 0주의 COX 주식에 해당합니다.
주식 분할 목록
연도 주식 분할 배수 누적 배수
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 주식 분할
회사 주식 분할 횟수 누적 배수 국가
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 1 x2
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 0 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 0 -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 0 -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 0 -
BE